Acadia Pharma (ACAD) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM EST- Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17
- Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017
- Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019
- 2019 Guidance: Net Sales $275 Million to $300 Million
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,... More
